CLINICAL TRIALS PROFILE FOR MEROPENEM; VABORBACTAM
✉ Email this page to a colleague
All Clinical Trials for meropenem; vaborbactam
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT02166476 ↗ | Efficacy/Safety of Meropenem-Vaborbactam Compared to Piperacillin-Tazobactam in Adults With cUTI and AP | Completed | Department of Health and Human Services | Phase 3 | 2014-11-20 | Meropenem-vaborbactam is being compared to piperacillin-tazobactam in the treatment of adults with complicated urinary tract infection (cUTI) or acute pyelonephritis (AP). |
| NCT02166476 ↗ | Efficacy/Safety of Meropenem-Vaborbactam Compared to Piperacillin-Tazobactam in Adults With cUTI and AP | Completed | Melinta Therapeutics, Inc. | Phase 3 | 2014-11-20 | Meropenem-vaborbactam is being compared to piperacillin-tazobactam in the treatment of adults with complicated urinary tract infection (cUTI) or acute pyelonephritis (AP). |
| NCT02166476 ↗ | Efficacy/Safety of Meropenem-Vaborbactam Compared to Piperacillin-Tazobactam in Adults With cUTI and AP | Completed | Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company) | Phase 3 | 2014-11-20 | Meropenem-vaborbactam is being compared to piperacillin-tazobactam in the treatment of adults with complicated urinary tract infection (cUTI) or acute pyelonephritis (AP). |
| NCT02168946 ↗ | Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults | Completed | Department of Health and Human Services | Phase 3 | 2014-07-01 | Vabomere™, (meropenem-vaborbactam) is being compared to the Best Available Therapy in the treatment of adults with selected serious infections due to Carbapenem Resistant Enterobacteriaceae |
| NCT02168946 ↗ | Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults | Completed | Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.) | Phase 3 | 2014-07-01 | Vabomere™, (meropenem-vaborbactam) is being compared to the Best Available Therapy in the treatment of adults with selected serious infections due to Carbapenem Resistant Enterobacteriaceae |
| NCT02168946 ↗ | Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults | Completed | Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company) | Phase 3 | 2014-07-01 | Vabomere™, (meropenem-vaborbactam) is being compared to the Best Available Therapy in the treatment of adults with selected serious infections due to Carbapenem Resistant Enterobacteriaceae |
| NCT02687906 ↗ | Dose-finding, Pharmacokinetics, and Safety of VABOMERE in Pediatric Subjects With Bacterial Infections | Recruiting | Department of Health and Human Services | Phase 1 | 2016-07-01 | A single dose infusion of Vabomere (meropenem-vaborbactam) is being tested for dose-finding, pharmacokinetics, safety, and tolerability in pediatric subjects from birth to less than 18 years of age with serious bacterial infections |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for meropenem; vaborbactam
Condition Name
Clinical Trial Locations for meropenem; vaborbactam
Trials by Country
Clinical Trial Progress for meropenem; vaborbactam
Clinical Trial Phase
Clinical Trial Sponsors for meropenem; vaborbactam
Sponsor Name
| Sponsor Name for meropenem; vaborbactam | |
| Sponsor | Trials |
| Department of Health and Human Services | 3 |
| Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company) | 3 |
| Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.) | 3 |
| [disabled in preview] | 3 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
